Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.
Ghent, Belgium, 10 March 2022 – Following the launch of the cluster flanders.healthTech in 2021, the first round of 14 consortia have started working on innovation projects in healthcare. The projects have received a total of EUR 4.7 million in VLAIO support from Flemish Minister of Economy and Innovation Hilde Crevits to help make a difference in the field of technology and innovation in healthcare.
Leuven, Belgium, 17 February 2022 - miDiagnostics, a fast-growing POC diagnostics company backed by Belgian Family Offices, announces the success of the Brussels Airport pilot study for its ultra-fast COVID-19 PCR Test. This test is the first of many applications for miDiagnostics’ disruptive technology, licensed from imec (Leuven, Belgium) and developed in close collaboration with Johns Hopkins University. The study confirms that the test can perform rapid and high-quality diagnostics on the spot in a real-life setting, providing travelers with a result within half an hour with the same accuracy as a traditional PCR test.
Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.
Ghent, Belgium, 10 March 2022 – Following the launch of the cluster flanders.healthTech in 2021, the first round of 14 consortia have started working on innovation projects in healthcare. The projects have received a total of EUR 4.7 million in VLAIO support from Flemish Minister of Economy and Innovation Hilde Crevits to help make a difference in the field of technology and innovation in healthcare.
Leuven, Belgium, 17 February 2022 - miDiagnostics, a fast-growing POC diagnostics company backed by Belgian Family Offices, announces the success of the Brussels Airport pilot study for its ultra-fast COVID-19 PCR Test. This test is the first of many applications for miDiagnostics’ disruptive technology, licensed from imec (Leuven, Belgium) and developed in close collaboration with Johns Hopkins University. The study confirms that the test can perform rapid and high-quality diagnostics on the spot in a real-life setting, providing travelers with a result within half an hour with the same accuracy as a traditional PCR test.